| Document |
Document Title |
|
WO/2023/173717A1 |
The present invention relates to a preparation method for an intermediate compound acting as a posaconazole synthetic drug, and an intermediate compound prepared thereby. The preparation method for a compound of formula (I) provided by t...
|
|
WO/2023/174905A1 |
A process for the production of glycolic acid comprising subjecting an aqueous oxalic acid solution to a hydrogenation reaction in the presence of hydrogen and a metal containing hydrogenation catalyst, wherein the process is a continuou...
|
|
WO/2023/173227A1 |
Disclosed are novel C4-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same, including C4-ether-substituted tryptamine derivative compounds, C4-carbonic ester- substituted ...
|
|
WO/2023/176687A1 |
The present invention addresses the problem of providing a novel dicarboxylic acid compound that has a further improved refractive index. The solution is to provide a biphenanthrene compound, represented by general formula (1), or an alk...
|
|
WO/2023/174409A1 |
The present invention relates to a salt form and a crystal form of a Vanin enzyme inhibitor represented by formula I, a method for preparing same, and use thereof. The salt form is a salt formed by the compound represented by formula I w...
|
|
WO/2023/173229A1 |
Disclosed are salts of C4-carboxylic acid-substituted and C4-carbonothioate-substituted tryptamine derivative compounds represented by chemical formula (I), wherein R4 is a carboxylic acid moiety or a derivative thereof, or a carbonothio...
|
|
WO/2023/173066A1 |
Described in this application are proteins and host cells involved in methods of producing absisic acid (ABA) precursors and/or ABA.
|
|
WO/2023/169520A1 |
The use of an arylvinyl α-carbonyl acid ester compound (I) as a photoinitiator in LED photopolymerization and a preparation method therefor, which relate to the field of polymer photocuring, and are provided on the basis of the problems...
|
|
WO/2023/167325A1 |
The present invention addresses the problem of developing a metal catalyst which is suitable for continuous flow organic synthesis reaction, is excellent in durability, and has high activity.　The present invention provides an immobiliz...
|
|
WO/2023/097398A9 |
A composition is provided for treating and/or preventing inflammation in a subject comprising A-type proanthocyanidin (PAC-A) and zinc. The composition can include between 0.001 wt% and 10 wt% of PAC-A, and between 0.01 wt% and 25 wt% of...
|
|
WO/2023/161483A1 |
The invention pertains to a method for manufacturing sodium lactate (NaL) solid particles, characterized in that the method comprises the following steps: - providing a melt of NaL wherein the melt has a chemical purity of at least 95 %....
|
|
WO/2023/163369A1 |
The present invention relates to a method for preparing nano calcium citrate and, specifically, to a method for preparing nano calcium citrate, comprising the steps of: dissolving citric acid in a solvent of ethanol and water (step 1); a...
|
|
WO/2023/160672A1 |
The present disclosure provides LPA antagonists of formula I, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.
|
|
WO/2023/155797A1 |
Provided is a method for purifying L-lactic acid, comprising the following steps: (1) a manufacturing procedure; (2) a circulating procedure; (3) a water-jacking-material procedure: using water to conduct water jacking on a cation exchan...
|
|
WO/2023/147665A1 |
The present disclosure relates to compositions for improving gut health and/or milk production in ruminants, comprising: at least one organic acid chosen from sorbic acid, fumaric acid, malic acid, lactic acid, citric acid, formic acid, ...
|
|
WO/2023/146975A1 |
Disclosed are compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods of preparation thereof, wherein R1, Xa, Xb, Xc, and Xd are as described in the specification. Further disclosed is an isotopic mixture of a co...
|
|
WO/2023/144108A1 |
The present invention relates to a process for preparing para-hydroxycinnamic acid from para-hydroxybenzaldehydes by condensation with malonic acid.
|
|
WO/2023/134712A1 |
Provided herein are novel compounds (e.g., Formula I, II, II-B, III, or III-B), pharmaceutical compositions, and methods of using related to GPR40. The compounds herein are typically GPR40 agonists, which can be used for treating a varie...
|
|
WO/2023/133524A1 |
Disclosed herein is a process for synthesizing ketanserin with improved yield and efficiency. In addition several toxic materials were eliminated from the process.
|
|
WO/2023/126480A1 |
A method for treating a mixture of textile fibers comprising PLA textile fibers and non-PLA textile fibers, wherein the mixture of fibers is introduced into a tank with a solvent for PLA in a PLA/lactic ester mass ratio between 0.05 and ...
|
|
WO/2023/120446A1 |
This anthraquinone active material for a redox flow battery contains a compound represented by the following chemical formula, and at least one of R2, R3, R6, and R7 represents a hydroxyl group or an alkoxy group.
|
|
WO/2023/120450A1 |
In this method for producing anthraquinones represented by the chemical formula, at least one of R1-R8 is a hydroxyl group and at least one is an alkoxy group. The production method includes a step for preparing a starting material that ...
|
|
WO/2023/120445A1 |
This anthraquinone active substance for redox flow batteries includes a first compound represented by a chemical formula. With respect to R1 to R8, at least one is a hydroxyl group and at least one is an alkoxy group.
|
|
WO/2023/109855A1 |
The present invention relates to a pharmaceutical cocrystal of curcumin, a preparation method therefor, and the use thereof as a drug or in a pharmaceutical preparation. The pharmaceutical cocrystal of curcumin has a good solubility, a g...
|
|
WO/2023/108277A1 |
The present invention relates to application of hydrotropic agents in making water-soluble and super-fast disintegrating tablets, buccal tablets, or sublingual tablets containing either cannabinoid molecules or psychedelics molecules. Th...
|
|
WO/2023/107412A1 |
Chemical compounds/compositions, methods of synthesis, and methods of use are provided. The compounds/compositions are directed toward thyrointegrin antagonists directly conjugated to a polymer. The compounds/compositions may further com...
|
|
WO/2023/098853A1 |
The present invention relates to a cocrystal of cabozantinib, a preparation method therefor and an application thereof as a drug or in a pharmaceutical preparation, more particularly an application for the treatment of progressive medull...
|
|
WO/2023/099353A1 |
A process for converting carboxylic acid salts produced in bioprocesses into carboxylic acids, the process comprising (a) obtaining a carboxylate stream from a bioreactor, the carboxylate stream optionally comprising nutrient salt impuri...
|
|
WO/2023/100574A1 |
Provided are: a radiation-sensitive resin composition that can be formed into a resist film having satisfactory levels of sensitivity and CDU performance even when a next-generation technology is applied; and a pattern formation method.ã...
|
|
WO/2023/096366A1 |
The present invention relates to a process for recovery of 3-hydroxypropionic acid, a precipitate prepared in the process for recovery of 3-hydroxypropionic acid, and a slurry composition containing 3-hydroxypropionic acid, the method co...
|
|
WO/2023/096439A1 |
The present invention relates to a process of recovering 3-hydroxypropionic acid, the method comprising the steps of: forming crystals of 3-hydroxypropionate in a concentrate comprising 3-hydroxypropionic acid in the presence of an alkal...
|
|
WO/2023/096457A1 |
The present invention relates to a method for collecting an alkali metal salt hydrate and 3-hydroxypropionic acid, comprising the steps of: forming a crystal of 3-hydroxypropionate in a concentrated solution containing 3-hydroxypropionic...
|
|
WO/2023/096456A1 |
The present invention relates to: a crystal of 3-hydroxypropionic acid salt which includes an alkali metal salt of 3-hydroxypropionic acid or a hydrate thereof, and has a first peak at a predetermined diffraction angle (2θ±0.2°) of an...
|
|
WO/2023/092231A1 |
The invention relates to a pharmaceutical composition comprising a compound ALPHA-1062 or salt thereof, or to a compound ALPHA-1062 or salt thereof, for use in the treatment of confirmed or suspected traumatic brain injury (TBI) in a sub...
|
|
WO/2023/096461A1 |
The present invention relates to a process for recovering an alkali metal sulfate, comprising the steps of: forming an organic acid fermentation broth containing an alkali metal salt of an organic acid; and forming and recovering an alka...
|
|
WO/2023/072908A1 |
The present invention relates to new co-crystals of non-steroidal anti-inflammatory drugs (NSAIDs) belonging to the class of phenylpropionic or phenylacetic acid derivatives, Lysine and Gabapentin, to their pharmaceutical compositions an...
|
|
WO/2023/061437A1 |
The present invention relates to a salt of an antitumor drug and a crystal form thereof, and specifically relates to a pharmaceutical salt of the compound N-(3-(2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-
7-oxo-6-phenyl-8(7H)-...
|
|
WO/2022/115971A9 |
Disclosed are methods for separating, recovering, and purifying CBGA, CBDVA, THCVA, CBCVA, and CBCA from dewatered and desolventized crude complex extracts or mixtures of metabolites, cannabinoids, and cannabis phytochemicals. The method...
|
|
WO/2023/064363A1 |
The present disclosure relates to novel salts and salt forms of (2R)-2-(2-chlorophenyl)-2- (methylamino)cyclohexan-1-one (R-ketamine) and to processes for their preparation. The disclosure is also directed to pharmaceutical compositions ...
|
|
WO/2023/061372A1 |
The present invention relates to the field of medicinal chemistry, and in particular, to a malate salt of a xanomeline derivative, the malate salt having a structure as shown in formula (I). The malate salt of the compound of formula (I)...
|
|
WO/2023/062106A1 |
A process for producing vinyl esters of carboxylic acids, especially vinyl esters of ketocarboxylic acids, which can be α-ketocarboxylic acids or β-ketocarboxylic acids. The vinyl esters of the carboxylic acids in their vinyl group can...
|
|
WO/2023/058659A1 |
The purpose of the present invention is to provide: a new porous three-dimensional network structure applicable to a crystalline sponge method; a method for producing the porous three-dimensional network structure; and a new structural a...
|
|
WO/2023/047424A1 |
The present invention relates to a pharmaceutical acceptable iron (III) coordination complex having high phosphate binding capacity prepared through a cost-effective and an organic solvent free route. The present invention provides a pha...
|
|
WO/2023/039682A1 |
LSD derivative compounds and polymorphs thereof, methods for their synthesis, compositions and treatment of diseases and disorders are described herein, the compounds having the structure of Formula (I):, including pharmaceutically accep...
|
|
WO/2023/035068A1 |
An immunomodulatory combination including: (i) a lipid conjugate comprising an immunomodulatory agent covalently linked to a lipophilic moiety by a cleavable linkage or through a cleavable linker; and (ii) an antigen and/or one or more n...
|
|
WO/2023/038093A1 |
Provided is a deuterium-enriched composition comprising a deuterium-substituted carboxylic acid or a salt thereof, wherein the carboxylic acid or the salt thereof includes an α hydrogen of a carboxy group and a hydrogen other than the Î...
|
|
WO/2023/031285A1 |
The present invention relates to the field of organic synthesis, and in particular, the present invention pertains to a process for preparing a levulinic acid or salt thereof, or levulinate.
|
|
WO/2023/028376A1 |
Disclosed are surfactants, as well as methods of using thereof in oil and gas operations.
|
|
WO/2023/028378A1 |
Disclosed are compounds as well as methods of using thereof in oil and gas operations. The compounds described herein can be used in Enhanced Oil Recovery (EOR) formulations to provide aqueous stability and ultra-low interfacial tension ...
|
|
WO/2023/010213A1 |
The present invention provides anti-fungal compositions comprising at least one unsaturated fatty acid or a pharmaceutically acceptable salt thereof; at least one alpha-hydroxy acid or a pharmaceutically acceptable salt thereof; and at l...
|
